Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer

ABSTRACT: Intervention1: Masitinib, FOLFIRI: Masitinib will be taken orally, daily at 6mg/kg/day. FOLFIRI will be administered every 2 weeks Control Intervention1: Placebo, FOLFIRI: Placebo will be taken orally, daily. FOLFIRI will be administered every 2 weeks Primary outcome(s): Overall Survival (OS)Timepoint: till death or last follow up Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Participant and Investigator Blinded

DISEASE(S): Patients With Metastatic Colorectal Cancer

PROVIDER: 2577140 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Evaluate the effect of Nutraceutical Product (Onconeem) in patients with Colorectal Cancer

Project description:Intervention1: Onconeem: Onconeem 100 mg capsules will be taken twice daily along with SOC (palliative chemotherapy /radiotherapy of investigators choice) for a duration of 84 days Control Intervention1: Onconeem matching placebo: The placebo will be taken twice daily along with SOC (e.g., palliative chemotherapy/radiotherapy of investigator choice) for a duration of 84 days Primary outcome(s): Improvement in Quality of life (measured using FACT-G questionnaire) from baseline till End of treatment (EOT)Timepoint: Day 84 Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant and Investigator Blinded

| 30959 | ecrin-mdr-crc

Transcriptional profiling of FOLFIRI treated VAKPS Tumoroids

Project description:To determine the effects of chemotherapy on cell state dyanmics, VAKPS tumroids were treated with FOLFIRI or DMSO for 72hrs before analyzing their transcriptome. We then performed gene expression profiling analysis using data obtained from mRNA-seq of the indicated tumoroid lines.

2024-10-17 | GSE237837 | GEO

Colorectal cancer classification based on gene expression is not associated with FOLFIRI response

Project description:Sadanandam et al. (2013) recently published a study based on the use of microarray data to classify colorectal cancer (CRC) samples. The classification claimed to have strong clinical implications, as reflected in the paper title: “A colorectal cancer classification system that associates cellular phenotype and responses to therapy”. They defined five subtypes: (i) inflammatory; (ii) goblet-like; (iii) enterocyte; (iv) transit-amplifying; and (v) stem-like. Based on drug sensitivity data from 21 patients, they also reported that the so-called stem-like subtype show differential sensitivity to FOLFIRI. This is the key result in their publication, since it implies a direct relation between the subtype and the choice of CRC therapy (i.e. FOLFIRI response). However, our analyses using the same drug sensitivity data and results from additional patients showed that the CRC classification reported by Sadanandam et al. is not predictive of FOLFIRI response.

2014-09-10 | GSE54483 | GEO

Effect of turmeric extract in patients with colon cancer

Project description:Intervention1: Tab. Curcuma longa 550 mg: Tab. Curcuma longa 550 mg, 3 times a day daily from the day of initiation of chemotherapy to 8 cycles along with the CAPOX regimen Control Intervention1: Tab. Placebo: Tab. Placebo, 3 times a day daily from the day of initiation of chemotherapy to 8 cycles along with the CAPOX regimen Primary outcome(s): objective response rate (ORR) at the end of 8 cycles of treatment in metastatic colorectal patientsTimepoint: 0 cycle, 8 cycles of chemotherapy Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Permuted block randomization, variable Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant and Investigator Blinded

| 2758009 | ecrin-mdr-crc

Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis

Project description:This was a phase II, randomized, placebo-controlled, double-blinded single center study (clinicaltrials.gov: NCT01806662) to investigate safety and efficacy of ustekinumab treatment in moderate-to-severe AD patients. Patients underwent 1:1 randomization using a computer generated subject randomization table by an unblinded pharmacist. to Subjects received subcutaneous ustekinumab or placebo at weeks 0, 4, and 16 with a crossover to the other agent (either ustekinumab or placebo) at weeks 16, 20, and 32 (Figure 1A) to ensure patient retention.

2019-11-20 | GSE140684 | GEO

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Project description:The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.

| 2202343 | ecrin-mdr-crc

scRNAseq of mouse colorectal organoids in FOLFIRI treatment

Project description:The aim of the experiment is to elucidate changes in tumor heterogeneity upon chemotherapy treatment. The experiment includes non-treated samples, samples right after chemotherapy treatment (FOLFIRI) and organoids recovered from FOLFIRI. It was conducted in two different genetic backgrounds, AKP (Apc KO, KrasG12D and P53 KO) and APS (Apc KO, P53 and Smad4KO). In addition to that, the organoids carry an inducible Cre-ERT2 knock-in allele in the mex3a locus. Upon 4-OH-Tamoxifen induction, Mex3a cells will recombine the tracing allele stop-TdTomato, enabling the tracing of this subpopulation. To understand the fate of the traced cells, samples right after chemotherapy and in the recovery setting were sorted based on their tomato expression. This enables a single cell tracing experiment.

2022-05-13 | E-MTAB-11145 | biostudies-arrayexpress

Effects of oral melatonin and gabapentin on tube placement in trachea for anaesthesia in patient posted for surgery

Project description:Intervention1: Oral study drugs 120 min before induction of anaesthesia: To study Haemodynamic responses to both drugs Control Intervention1: Tablet Gabapentin: Oral Gabapentin 800 mg in study group will be given 120 min before induction of anaesthesia in double blind manner. Placebo tablets 120 min before induction of anaesthesia in control group Control Intervention2: Tab Melatonin: Tab melatonin 6 mg orally 120 min before induction of anaesthesia Primary outcome(s): SBP,DBP,MAP,HRTimepoint: Just after intubation,1min,3min,5min,10min Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant, Investigator and Outcome Assessor Blinded

| 2589334 | ecrin-mdr-crc